Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

121. Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention. (Abstract)

Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention. 32060537 2020 02 15 1522-9645 2020 Feb 14 European heart journal Eur. Heart J. Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention. ehaa081 10.1093/eurheartj/ehaa081 Agasthi Pradyumna P Department of Cardiovascular Disease, Mayo Clinic

2020 European Heart Journal

122. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. (Abstract)

Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. Background: Periprocedural uninterrupted anticoagulation for catheter ablation of atrial fibrillation (AF) became standard after positive results of vitamin K antagonist (VKA) trials. Previous studies of uninterrupted direct oral anticoagulants (DOACs

2020 Acta cardiologica

123. Effect of non-vitamin-K oral anticoagulants on stroke severity compared to warfarin: a meta-analysis of randomized controlled trials. (Abstract)

Effect of non-vitamin-K oral anticoagulants on stroke severity compared to warfarin: a meta-analysis of randomized controlled trials. In addition to lowering stroke risk, warfarin use is also associated with reduced stroke severity in patients with atrial fibrillation and acute ischaemic stroke. It was sought to determine whether the effect of non-vitamin-K oral anticoagulants (NOACs), compared to warfarin, differed by stroke severity.Phase III randomized controlled trials with participants who

2020 European Journal of Neurology

124. Extracorporeal membrane oxygenation without therapeutic anticoagulation in adults: A systematic review of the current literature. (Abstract)

Extracorporeal membrane oxygenation without therapeutic anticoagulation in adults: A systematic review of the current literature. Extracorporeal membrane oxygenation is essential for the treatment of refractory cardiopulmonary failure. Its use may be complicated by worse haemorrhagic complications exacerbated by extracorporeal membrane oxygenation-related therapeutic anticoagulation. Progressive technological advancements have made extracorporeal membrane oxygenation components less (...) thrombogenic, potentially allowing its application with temporary avoidance of systemic anticoagulants. A systematic review of all the available experiences, reporting the use of extracorporeal membrane oxygenation without systemic anticoagulation in the published literature was performed. Only patient series were included, irrespective of the clinical indication. The survival, extracorporeal membrane oxygenation system-related dysfunction and complications rates, as well as in-hospital outcome, were

2020 The International journal of artificial organs

125. Catheter ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six randomized controlled trials. (Abstract)

Catheter ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six randomized controlled trials. Uninterrupted anticoagulation is recommended during the ablation of atrial fibrillation. This meta-analysis compared the safety and efficacy of uninterrupted direct oral anticoagulants (DOACs) to uninterrupted vitamin K antagonists (VKAs) during atrial fibrillation ablation.The meta-analysis included eligible randomized controlled trials from 2009 to 2019. Odds

2020 Journal of cardiovascular medicine (Hagerstown, Md.)

126. The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. (Full text)

The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Background/Aims: Although acid suppressants are widely used for the prevention or treatment of drug-induced upper gastrointestinal bleeding (GIB), evidence regarding the prevention of anticoagulant-related GIB is scarce. The aim of this study was to evaluate the protective effect of acid suppressants against anticoagulant-related GIB. Methods: A systematic review was conducted of studies that evaluated the protective effect of acid suppressants against anticoagulant-related GIB found in PubMed, the Cochrane library, Embase, and KoreaMed from the date of database inception to April 2018. Random effect model meta-analyses with sensitivity analyses were conducted. The methodological quality of each included publication was evaluated using the Risk of Bias Assessment Tool for Nonrandomized Studies. Publication bias was assessed. Results:

2020 Gut and liver PubMed abstract

127. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis (Abstract)

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown.This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term (...) for dabigatran and rivaroxaban were limited to major bleeding events. Compared with no anticoagulants, apixaban and warfarin were not associated with a significant decrease in stroke and/or systemic thromboembolism (apixaban 5 mg, hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.30 to 1.17; apixaban 2.5 mg, HR: 1.00; 95% CI: 0.52 to 1.93; warfarin, HR: 0.91; 95% CI: 0.72 to 1.16). Apixaban 5 mg was associated with a significantly lower risk of mortality (vs. warfarin, HR: 0.65; 95% CI: 0.45 to 0.93

2020 EvidenceUpdates

128. High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants Prescrire IN ENGLISH - Spotlight ''High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants'', 1 February 2020 {1} {1} {1} | | > > > High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight In the February issue of Prescrire International - High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants FREE DOWNLOAD In the Adverse Effects section this month: should patients taking a direct oral anticoagulant switch to a vitamin K agonist such as warfarin, in light of the French drug regulatory agency's recent advisory? Full text available for free download. Summary In mid-2019, the French drug regulatory agency, ANSM

2020 Prescrire

129. Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis (Abstract)

Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis  In this study-level meta-analysis, we evaluated the clinical outcome with nonvitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with cancer. Anticoagulation in AF patients with cancer is challenging given the coexistence of elevated thrombotic and bleeding risk. The efficacy and safety

2020 EvidenceUpdates

130. Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. (Full text)

Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. Direct oral anticoagulants (DOACs) are effective treatment for venous thromboembolism. However, safety data in patients with cirrhosis are limited. We conducted a systematic review and meta-analysis to evaluate the safety of DOACs compared with warfarin or low-molecular weight heparin in patients with cirrhosis.A systematic literature search was performed using MEDLINE and EMBASE from (...) inception up to June 2018. We included prospective and retrospective studies involving adults ≥18 years with cirrhosis in whom anticoagulants were indicated for any indications. Primary outcome was all-cause bleeding events. Secondary outcome was major bleeding. Pooled risk ratio, pooled odd ratios and 95% confidence intervals (CIs) were calculated using random-effects model.Five studies with a total of 447 patients were included in the analysis. When compared with controls, the use of DOACs

2020 QJM : monthly journal of the Association of Physicians PubMed abstract

131. Letter to the Editor concerning: "A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants". (Abstract)

Letter to the Editor concerning: "A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants". 31522766 2020 01 27 2020 01 27 1874-1754 297 2019 12 15 International journal of cardiology Int. J. Cardiol. Letter to the Editor concerning: "A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety (...) following treatment with direct oral anticoagulants". 66 S0167-5273(19)33105-5 10.1016/j.ijcard.2019.07.012 Enache Bogdan B University of Medicine and Pharmacy "Victor Babes", Timisoara, Romania; Princess Grace Hospital, Monaco. Electronic address: bogdi.enache@gmail.com. Chen Yang Y Institute of Cardiovascular Science UCL, London, United Kingdom. eng Letter Comment 2019 09 12 Netherlands Int J Cardiol 8200291 0167-5273 0 Anticoagulants 5Q7ZVV76EI Warfarin IM Int J Cardiol. 2018 Oct 15;269:174-181

2020 International journal of cardiology

132. The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: A systemic review and meta-analysis. (Full text)

The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: A systemic review and meta-analysis. This meta-analysis was to investigate the efficacy and safety of new oral anticoagulant (NOAC) in atrial fibrillation (AF) patients with renal function insufficiency, and to explore whether renal decline occurs in AF patients with NOAC and its impact on outcomes.In AF patients with mild renal insufficiency, the NOAC was associated with significantly (...) with renal impairment. Renal decline during therapeutics may be less likely happened in NOAC than warfarin dose. NOAC may reveal good efficacy and safety outcomes in these scenarios. Further detailed research is needed to gain more clear profile on this new anticoagulant.

2020 Medicine PubMed abstract

133. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta-analysis. (Full text)

Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta-analysis. The risk and benefit of periprocedural heparin bridging is not completely clarified. We aimed to assess the safety and efficacy of bridging anticoagulation prior to invasive procedures or surgery. Heparin bridging was associated with lower risks of thromboembolism and bleeding compared to non-bridging. PubMed, Ovid and Elsevier, and Cochrane Library (2000-2016) were searched (...) for English-language studies. Studies comparing interrupted anticoagulation with or without bridging and continuous oral anticoagulation in patients at moderate-to-high thromboembolic risk before invasive procedures were included. Primary outcomes were thromboembolic events and bleeding events. Mantel-Haenszel method and random-effects models were used to analyze the pooled risk ratio (RR) and 95% confidence interval (CI) for thromboembolic and bleeding risks. Eighteen studies (six randomized controlled

2020 Clinical cardiology PubMed abstract

134. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis. (Abstract)

Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis. Direct oral anticoagulants (DOACs) effectively prevent recurrent venous thromboembolism (VTE). However, it is unknown which agents should be used to prevent recurrent VTE and which patients with unprovoked VTE should receive extended anticoagulation. We therefore sought to compare the efficacy and safety (...) among DOACs for secondary prevention of VTE. We also determined a risk-adapted threshold for initiating extended anticoagulation based on the likelihood of VTE recurrence (without treatment) and bleeding (with treatment) in patients with unprovoked VTE.Our systematic review of randomized controlled trials compares extended anticoagulation with DOACs to another DOAC, aspirin, or placebo for the prevention of recurrent VTE. We searched PubMed, EMBASE, and Cochrane Registry of Controlled Trials

2020 Journal of evaluation in clinical practice

135. Should Every Patient With Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients. (Abstract)

Should Every Patient With Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients. Patients with atrial fibrillation (AF) are at risk of thromboembolic events. The CHA2DS2-VASc (congestive heart failure, hypertension, age 65-74, diabetes, female sex and vascular disease, which all count for 1 point, and previous transient ischemic stroke/stroke or age ≥ 75 years, which count for two points) score stratifies this risk and consequently indicates (...) whether anticoagulation is required but leaves room for debate regarding patients with a CHA2DS2-VASc score of 1, irrespective of sex. A score of 1, irrespective of sex, is derived from varying risk factors and may represent different risks. We systematically searched PubMed from inception to July 31, 2017, for studies describing thromboembolic risk per risk factor of the CHA2DS2-VASc score in patients with AF not treated with an anticoagulant. Two independent reviewers selected, appraised

2020 Cardiology in Review

136. Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. (Abstract)

Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the pharmacoeconomic impact of oral anticoagulants (OACs) including warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban in SPAF in Taiwan.A decision tree, Markov model, and multiple sensitivity analyses

2020 Acta Cardiologica Sinica

137. Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta-analysis. (Abstract)

Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta-analysis. Oral anticoagulation (OAC) is prescribed for left atrial thrombi (LAT) in nonrheumatic atrial fibrillation (AF) and/or atrial flutter (AFL). The study objective was to review the existing evidence regarding LAT resolution in nonrheumatic AF and/or AFL with OAC agents.Data sources included PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (...) studies.The pooled LAT resolution rate of 619 subjects from 16 VKA studies was 63.7% (95% confidence interval [CI], 53.3%-72.9%). The pooled LAT resolution rate of 94 subjects from four studies that specified warfarin use, exclusion of prior long-term therapeutic OAC, and target international normalized ratio (INR) ≥ 2.0 and/or average achieved INR ≥ 2.0 was 79.3% (95% CI, 69.8%-86.4%). Two studies in direct-acting oral anticoagulants (DOACs) reported LAT resolution rates of 89.5% (17 of 19

2020 Pacing and clinical electrophysiology : PACE

138. Instruments for the assessment of patient adherence to oral anticoagulation with warfarin protocol for a systematic review. (Full text)

Instruments for the assessment of patient adherence to oral anticoagulation with warfarin protocol for a systematic review. Non-adherence can be highlighted as one of the main contributors to the occurrence of adverse events in patients treated with warfarin. The usefulness of self-reporting measures of drug adherence could be improved by following psychometric properties in the development of the measurement scales. Thus, we aimed to describe the protocol of a systematic literature review

2020 Medicine PubMed abstract

139. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis. (Abstract)

Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Selection of an appropriate antithrombotic regimen in patients requiring oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) still remains a challenge. An ideal 9-2regimen should balance the risk of bleeding against ischemic benefit.A comprehensive literature search for studies comparing triple

2020 Journal of cardiovascular electrophysiology

140. Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. (Full text)

Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. 31524175 2020 01 08 1875-8908 71 4 2019 Journal of Alzheimer's disease : JAD J. Alzheimers Dis. Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. 1375-1378 10.3233/JAD-199005 Fanning Laura L Ryan-Atwood Taliesin E TE Bell

2020 Journal of Alzheimer's disease : JAD PubMed abstract